Abstract: A display device and method for manufacturing thereof are provided. The display device includes a substrate having a display area and a non-display area, and including an edge, an upper surface having an edge area in which a processing trace remains adjacent to the edge, a bottom surface opposite to the upper surface, a side surface connected to the upper surface and not parallel thereto, and a first inclined surface connected to the side surface and to the bottom surface, a light-emitting element layer above the upper surface of the substrate in the display area, and including light-emitting elements, an encapsulating layer above the light-emitting element layer and corresponding to a portion of the display area and the non-display area, and a protective layer above an outer surface of the substrate, and located on at least one of the bottom surface, the side surface, or the first inclined surface.

Abstract: A display device includes: a substrate including a display area and a non-display area surrounding the display area; a light emitting element layer on the display area on the substrate and including a plurality of light emitting elements; and an encapsulating layer on the light emitting element layer and on a portion of the display area and the non-display area; and wherein the substrate comprises an upper surface on which the light emitting element layer is located, a bottom surface opposite to the upper surface, a side surface connected to the upper surface and not parallel to the upper surface, and a first inclined surface connected to the side surface and the bottom surface and not parallel to the side surface and the bottom surface, wherein an edge area of the upper surface of the substrate adjacent to an edge of the substrate, in which a processing trace remains.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A display device includes: a substrate comprising an upper surface, a bottom surface facing the upper surface, and a through hole penetrating the upper surface and the bottom surface; and a light emitting element layer on the upper surface of the substrate, wherein the substrate comprises a side surface that meets the upper surface in the through hole, a first surface that meets the bottom surface, a second surface that meets the side surface, and a third surface between the first surface and the second surface, and wherein the first surface and the second surface are spaced apart from each other with the third surface therebetween, and are inclined surfaces.

Abstract: An electronic device includes a display device, which may be fabricated using a described method. The display device includes a glass substrate including a first surface, a second surface opposite the first surface, and a side surface between the first surface and the second surface, an outermost structure on the first surface of the glass substrate and located adjacent to an edge of one side of the glass substrate, and a display area including a plurality of light emitting areas on the first surface of the glass substrate and located farther from the edge of the one side of the glass substrate than the outermost structure is. A minimum distance from the side surface of the glass substrate to the outermost structure is equal to 130 ?m or less.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: A mask according to one embodiment of the present invention is worn on the face of a user, and comprises: a mask body made from a first transparent material; and a filter unit coupled to the mask body and made from a material through which air can be ventilated, wherein the mask body is formed in a region corresponding to the nose and mouth of the user.

Abstract: An eye disease diagnosis method using artificial intelligence may include: collecting, from a database, a first eyeground image of a myopic patient who is not diagnosed with an eye disease and a second eyeground image of a myopic patient who has been diagnosed with the eye disease; learning eyeball change information by degree of myopia based on the first eyeground image, using deep learning; comparing and analyzing the first eyeground image and the second eyeground image based on the eyeball change information by the degree of myopia, and learning eyeball change information by the eye disease using deep learning; and estimating determination criteria of an eyeground image for diagnosis of the eye disease, based on a difference between the eyeball change information by the degree of myopia and the eyeball change information by the eye disease.

Abstract: An eye disease diagnosis method using artificial intelligence may include: collecting, from a database, a first eyeground image of a myopic patient who is not diagnosed with an eye disease and a second eyeground image of a myopic patient who has been diagnosed with the eye disease; learning eyeball change information by degree of myopia based on the first eyeground image, using deep learning; comparing and analyzing the first eyeground image and the second eyeground image based on the eyeball change information by the degree of myopia, and learning eyeball change information by the eye disease using deep learning; and estimating determination criteria of an eyeground image for diagnosis of the eye disease, based on a difference between the eyeball change information by the degree of myopia and the eyeball change information by the eye disease.

Abstract: A method of driving a display device includes displaying both a natural image and a color vision test image on the display unit. The color vision test image is an image used to determine whether a person has a color vision impairment. A color adjustment user interface for adjusting color of the display unit is displayed on the display unit. A color adjustment instruction that instructs to adjust color of the display unit is received via an input unit. Supply image data supplied to the display unit is adjusted based on the color adjustment instruction by using a controller.

Abstract: The present invention relates to a liquid-crystalline medium, characterized in that it contains a polymerizable component (A) containing one more polymerizable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterised in that it contains a polymerisable component (A) containing one more polymerisable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterized in that it contains a polymerizable component (A) containing one more polymerizable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterised in that it contains a polymerisable component (A) containing one more polymerisable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterised in that it contains a polymerisable component (A) containing one more polymerisable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterised in that it contains a polymerisable component (A) containing one more polymerisable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterised in that it contains a polymerisable component (A) containing one more polymerisable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.

Abstract: The present invention relates to a liquid-crystalline medium, characterised in that it contains a polymerisable component (A) containing one more polymerisable compounds and a liquid-crystalline component (B) containing one more compounds of the general formula I in which R, rings A1 and A2, Z1, Z2, Y1, Y2, X0 and r are as defined in Claim 1.